CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于工程化T淋巴细胞内源性分泌T细胞重定向双特异性抗体的癌症免疫治疗策略(STAb-T)正在成为基于嵌合抗原受体(CAR-T)策略的替代或补充方法。分泌双特异性抗CD19抗CD3(CD19 CD3)T细胞衔接器(BiTE)的STAb-T细胞的抗肿瘤疗效已在多个B细胞急性白血病小鼠模型中得到证实。
在此,我们研究了由CAR-T 或STAb-T细胞形成的人工免疫突触(IS)的空间拓扑结构和下游信号传导。与CD19阳性靶细胞相互作用后,STAb-T细胞形成的IS在结构和信号转导方面更接近生理性同源IS,相比之下,表达携带相同CD19-单链可变片段的第二代CAR的CAR-T 细胞所形成的IS则不然。
重要的是,虽然CD3在STAb-T细胞表面维持可检测水平,表明由分泌的BiTE介导的持续激活,但抗CD19 CAR迅速下调,这与更短暂的下游信号传导相关。
此外,CAR-T 细胞而非STAb-T细胞会引发靶细胞中CD19的急性丢失。这些差异可能代表STAb-T策略相对于CAR-T 方法的优势,应予以仔细考虑,以开发更有效、更安全的血液恶性肿瘤治疗方法。
Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The antitumor efficacy of bispecific anti-CD19 anti-CD3 (CD19 CD3) T cell engager (BiTE)-secreting STAb-T cells has been demonstrated in several mouse models of B-cell acute leukemia.
Here, we have investigated the spatial topology and downstream signaling of the artificial immunological synapses (IS) that are formed by CAR-T or STAb-T cells. Upon interaction with CD19-positive target cells, STAb-T cells form IS with structure and signal transduction, which more closely resemble those of physiological cognate IS, compared to IS formed by CAR-T cells expressing a second-generation CAR bearing the same CD19-single-chain variable fragment.
Importantly, while CD3 is maintained at detectable levels on the surface of STAb-T cells, indicating sustained activation mediated by the secreted BiTE, the anti-CD19 CAR was rapidly downmodulated, which correlated with a more transient downstream signaling.
Furthermore, CAR-T cells, but not STAb-T cells, provoke an acute loss of CD19 in target cells. Such differences might represent advantages of the STAb-T strategy over the CAR-T approach and should be carefully considered in order to develop more effective and safer treatments for hematological malignancies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。